{"pmid":32482077,"title":"Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead.","text":["Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead.","The global COVID-19 pandemic has oversaturated many intensive care units to the point of collapse, leading to enormous spikes in death counts. Before critical care becomes a necessity, identifying patients who are likely to become critically ill and providing prompt treatment is a strategy to avoid ICU oversaturation. There is a consensus that a hyperinflammatory syndrome or a \"cytokine storm\" is responsible for poor outcomes in COVID-19. Measuring cytokine levels at the point of care is required in order to better understand this process. In this Perspective paper we summarize the main events behind the cytokine storm in COVID-19 as well as current experimental treatments. We advocate for a new biosensor-enabled paradigm to personalize the management of COVID-19 and stratify patients. Biosensor-guided dosing and timing of immunomodulatory therapies could maximize the benefits of these anti-inflammatory treatments while minimizing deleterious effects. Biosensors will also be essential in order to detect complications such as co-infections and sepsis, which are common in immunosuppressed patients. Finally, we propose the ideal features of these biosensors using some prototypes from the recent literature as examples. Multisensors, lateral flow tests, mobile biosensors and wearable biosensors are seen as key players for precision medicine in COVID-19.","ACS Sens","Russell, Steven M","Alba-Patino, Alejandra","Baron, Enrique","Borges, Marcio","Gonzalez-Freire, Marta","de la Rica, Roberto","32482077"],"abstract":["The global COVID-19 pandemic has oversaturated many intensive care units to the point of collapse, leading to enormous spikes in death counts. Before critical care becomes a necessity, identifying patients who are likely to become critically ill and providing prompt treatment is a strategy to avoid ICU oversaturation. There is a consensus that a hyperinflammatory syndrome or a \"cytokine storm\" is responsible for poor outcomes in COVID-19. Measuring cytokine levels at the point of care is required in order to better understand this process. In this Perspective paper we summarize the main events behind the cytokine storm in COVID-19 as well as current experimental treatments. We advocate for a new biosensor-enabled paradigm to personalize the management of COVID-19 and stratify patients. Biosensor-guided dosing and timing of immunomodulatory therapies could maximize the benefits of these anti-inflammatory treatments while minimizing deleterious effects. Biosensors will also be essential in order to detect complications such as co-infections and sepsis, which are common in immunosuppressed patients. Finally, we propose the ideal features of these biosensors using some prototypes from the recent literature as examples. Multisensors, lateral flow tests, mobile biosensors and wearable biosensors are seen as key players for precision medicine in COVID-19."],"journal":"ACS Sens","authors":["Russell, Steven M","Alba-Patino, Alejandra","Baron, Enrique","Borges, Marcio","Gonzalez-Freire, Marta","de la Rica, Roberto"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32482077","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1021/acssensors.0c00979","topics":["Treatment"],"weight":1,"_version_":1668704334471233536,"score":9.490897,"similar":[{"pmid":32349033,"title":"Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2.","text":["Novel biosensor platforms for the detection of coronavirus infection and SARS-CoV-2.","The recent outbreak of the SARS-CoV-2 pandemic has been causing respiratory diseases globally, damaging wide-ranges of social-economical activities. This virus is transmitted through personal contact and possibly also through ambient air. Effective biosensor platforms for the detection of this virus and the related host response are in urgent demand. These platforms can facilitate routine diagnostic assays in certified clinical labs. They can also be integrated into point-of-care products. Furthermore, environmental biosensors can be designed to detect SARS-CoV-2 in the ambient air or in the intensive care ventilators. Here, we evaluate technical components of biosensors, including the biological targets of recognition, the recognition methods and the signal amplification and transduction systems. Effective SARS-CoV-2 detectors can be designed by adequate combination of these technologies.","J Chin Med Assoc","Liang, Kung-Hao","Chang, Tai-Jay","Wang, Mong-Lien","Tsai, Ping-Hsing","Lin, Ta-Hsien","Wang, Chin-Tien","Yang, De-Ming","32349033"],"abstract":["The recent outbreak of the SARS-CoV-2 pandemic has been causing respiratory diseases globally, damaging wide-ranges of social-economical activities. This virus is transmitted through personal contact and possibly also through ambient air. Effective biosensor platforms for the detection of this virus and the related host response are in urgent demand. These platforms can facilitate routine diagnostic assays in certified clinical labs. They can also be integrated into point-of-care products. Furthermore, environmental biosensors can be designed to detect SARS-CoV-2 in the ambient air or in the intensive care ventilators. Here, we evaluate technical components of biosensors, including the biological targets of recognition, the recognition methods and the signal amplification and transduction systems. Effective SARS-CoV-2 detectors can be designed by adequate combination of these technologies."],"journal":"J Chin Med Assoc","authors":["Liang, Kung-Hao","Chang, Tai-Jay","Wang, Mong-Lien","Tsai, Ping-Hsing","Lin, Ta-Hsien","Wang, Chin-Tien","Yang, De-Ming"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349033","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1097/JCMA.0000000000000337","topics":["Diagnosis"],"weight":1,"_version_":1666138495019646976,"score":190.25046},{"pmid":32364936,"pmcid":"PMC7152911","title":"Electrochemical biosensors for pathogen detection.","text":["Electrochemical biosensors for pathogen detection.","Recent advances in electrochemical biosensors for pathogen detection are reviewed. Electrochemical biosensors for pathogen detection are broadly reviewed in terms of transduction elements, biorecognition elements, electrochemical techniques, and biosensor performance. Transduction elements are discussed in terms of electrode material and form factor. Biorecognition elements for pathogen detection, including antibodies, aptamers, and imprinted polymers, are discussed in terms of availability, production, and immobilization approach. Emerging areas of electrochemical biosensor design are reviewed, including electrode modification and transducer integration. Measurement formats for pathogen detection are classified in terms of sample preparation and secondary binding steps. Applications of electrochemical biosensors for the detection of pathogens in food and water safety, medical diagnostics, environmental monitoring, and bio-threat applications are highlighted. Future directions and challenges of electrochemical biosensors for pathogen detection are discussed, including wearable and conformal biosensors, detection of plant pathogens, multiplexed detection, reusable biosensors for process monitoring applications, and low-cost, disposable biosensors.","Biosens Bioelectron","Cesewski, Ellen","Johnson, Blake N","32364936"],"abstract":["Recent advances in electrochemical biosensors for pathogen detection are reviewed. Electrochemical biosensors for pathogen detection are broadly reviewed in terms of transduction elements, biorecognition elements, electrochemical techniques, and biosensor performance. Transduction elements are discussed in terms of electrode material and form factor. Biorecognition elements for pathogen detection, including antibodies, aptamers, and imprinted polymers, are discussed in terms of availability, production, and immobilization approach. Emerging areas of electrochemical biosensor design are reviewed, including electrode modification and transducer integration. Measurement formats for pathogen detection are classified in terms of sample preparation and secondary binding steps. Applications of electrochemical biosensors for the detection of pathogens in food and water safety, medical diagnostics, environmental monitoring, and bio-threat applications are highlighted. Future directions and challenges of electrochemical biosensors for pathogen detection are discussed, including wearable and conformal biosensors, detection of plant pathogens, multiplexed detection, reusable biosensors for process monitoring applications, and low-cost, disposable biosensors."],"journal":"Biosens Bioelectron","authors":["Cesewski, Ellen","Johnson, Blake N"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364936","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.bios.2020.112214","keywords":["bio-threat","biosensors","covid-19","electrochemical","food safety","medical diagnostics","pathogen quantification","virus detection","water safety"],"e_drugs":["Water"],"weight":0,"_version_":1666138496118554624,"score":187.84877},{"pmid":32486477,"title":"Development of a Portable, Ultra-Rapid and Ultra-Sensitive Cell-Based Biosensor for the Direct Detection of the SARS-CoV-2 S1 Spike Protein Antigen.","text":["Development of a Portable, Ultra-Rapid and Ultra-Sensitive Cell-Based Biosensor for the Direct Detection of the SARS-CoV-2 S1 Spike Protein Antigen.","One of the key challenges of the recent COVID-19 pandemic is the ability to accurately estimate the number of infected individuals, particularly asymptomatic and/or early-stage patients. We herewith report the proof-of-concept development of a biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus. The biosensor is based on membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody. We demonstrate that the attachment of the protein to the membrane-bound antibodies resulted in a selective and considerable change in the cellular bioelectric properties measured by means of a Bioelectric Recognition Assay. The novel biosensor provided results in an ultra-rapid manner (3 min), with a detection limit of 1 fg/mL and a semi-linear range of response between 10 fg and 1 mug/mL. In addition, no cross-reactivity was observed against the SARS-CoV-2 nucleocapsid protein. Furthermore, the biosensor was configured as a ready-to-use platform, including a portable read-out device operated via smartphone/tablet. In this way, we demonstrate that the novel biosensor can be potentially applied for the mass screening of SARS-CoV-2 surface antigens without prior sample processing, therefore offering a possible solution for the timely monitoring and eventual control of the global coronavirus pandemic.","Sensors (Basel)","Mavrikou, Sophie","Moschopoulou, Georgia","Tsekouras, Vasileios","Kintzios, Spyridon","32486477"],"abstract":["One of the key challenges of the recent COVID-19 pandemic is the ability to accurately estimate the number of infected individuals, particularly asymptomatic and/or early-stage patients. We herewith report the proof-of-concept development of a biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus. The biosensor is based on membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody. We demonstrate that the attachment of the protein to the membrane-bound antibodies resulted in a selective and considerable change in the cellular bioelectric properties measured by means of a Bioelectric Recognition Assay. The novel biosensor provided results in an ultra-rapid manner (3 min), with a detection limit of 1 fg/mL and a semi-linear range of response between 10 fg and 1 mug/mL. In addition, no cross-reactivity was observed against the SARS-CoV-2 nucleocapsid protein. Furthermore, the biosensor was configured as a ready-to-use platform, including a portable read-out device operated via smartphone/tablet. In this way, we demonstrate that the novel biosensor can be potentially applied for the mass screening of SARS-CoV-2 surface antigens without prior sample processing, therefore offering a possible solution for the timely monitoring and eventual control of the global coronavirus pandemic."],"journal":"Sensors (Basel)","authors":["Mavrikou, Sophie","Moschopoulou, Georgia","Tsekouras, Vasileios","Kintzios, Spyridon"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32486477","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3390/s20113121","keywords":["bioelectric recognition assay (bera)","point-of-care (poc)","s1 spike protein","membrane engineering","serological assay","severe acute respiratory syndrome-coronavirus 2 (sars-cov-2)"],"topics":["Diagnosis"],"weight":1,"_version_":1668623433614753793,"score":176.3959},{"pmid":32431755,"pmcid":"PMC7220573","title":"The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the \"cytokine storm\" in COVID-19 patients: a hypothesis.","text":["The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the \"cytokine storm\" in COVID-19 patients: a hypothesis.","Background: A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a \"cytokine storm\". While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. Presentation of the hypothesis: A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. Testing the hypothesis: A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. Implications of hypothesis: If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit. Conclusions: In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19.","Patient Saf Surg","Thomas, Gregory","Frederick, Elizabeth","Hausburg, Melissa","Goldberg, Laura","Hoke, Marshall","Roshon, Michael","Mains, Charles","Bar-Or, David","32431755"],"abstract":["Background: A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a \"cytokine storm\". While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. Presentation of the hypothesis: A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. Testing the hypothesis: A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. Implications of hypothesis: If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit. Conclusions: In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19."],"journal":"Patient Saf Surg","authors":["Thomas, Gregory","Frederick, Elizabeth","Hausburg, Melissa","Goldberg, Laura","Hoke, Marshall","Roshon, Michael","Mains, Charles","Bar-Or, David"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431755","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s13037-020-00248-4","keywords":["acute lung injury","acute respiratory distress syndrome","barrier function","covid-19","cytokine storm","lmwf5a","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288238411777,"score":173.23502},{"pmid":32385712,"title":"Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","text":["Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?","Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19.","Cancer Metastasis Rev","Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D","32385712"],"abstract":["Severe coronavirus disease (COVID-19) is characterized by pulmonary hyper-inflammation and potentially life-threatening \"cytokine storms\". Controlling the local and systemic inflammatory response in COVID-19 may be as important as anti-viral therapies. Endogenous lipid autacoid mediators, referred to as eicosanoids, play a critical role in the induction of inflammation and pro-inflammatory cytokine production. SARS-CoV-2 may trigger a cell death (\"debris\")-induced \"eicosanoid storm\", including prostaglandins and leukotrienes, which in turn initiates a robust inflammatory response. A paradigm shift is emerging in our understanding of the resolution of inflammation as an active biochemical process with the discovery of novel endogenous specialized pro-resolving lipid autacoid mediators (SPMs), such as resolvins. Resolvins and other SPMs stimulate macrophage-mediated clearance of debris and counter pro-inflammatory cytokine production, a process called inflammation resolution. SPMs and their lipid precursors exhibit anti-viral activity at nanogram doses in the setting of influenza without being immunosuppressive. SPMs also promote anti-viral B cell antibodies and lymphocyte activity, highlighting their potential use in the treatment of COVID-19. Soluble epoxide hydrolase (sEH) inhibitors stabilize arachidonic acid-derived epoxyeicosatrienoic acids (EETs), which also stimulate inflammation resolution by promoting the production of pro-resolution mediators, activating anti-inflammatory processes, and preventing the cytokine storm. Both resolvins and EETs also attenuate pathological thrombosis and promote clot removal, which is emerging as a key pathology of COVID-19 infection. Thus, both SPMs and sEH inhibitors may promote the resolution of inflammation in COVID-19, thereby reducing acute respiratory distress syndrome (ARDS) and other life-threatening complications associated with robust viral-induced inflammation. While most COVID-19 clinical trials focus on \"anti-viral\" and \"anti-inflammatory\" strategies, stimulating inflammation resolution is a novel host-centric therapeutic avenue. Importantly, SPMs and sEH inhibitors are currently in clinical trials for other inflammatory diseases and could be rapidly translated for the management of COVID-19 via debris clearance and inflammatory cytokine suppression. Here, we discuss using pro-resolution mediators as a potential complement to current anti-viral strategies for COVID-19."],"journal":"Cancer Metastasis Rev","authors":["Panigrahy, Dipak","Gilligan, Molly M","Huang, Sui","Gartung, Allison","Cortes-Puch, Irene","Sime, Patricia J","Phipps, Richard P","Serhan, Charles N","Hammock, Bruce D"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385712","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s10555-020-09889-4","keywords":["covid-19","cytokine storms","eicosanoid storm","inflammation resolution","sars-cov-2"],"e_drugs":["Eicosanoids","Arachidonic Acid","Lipids","Prostaglandins","Leukotrienes"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102065881089,"score":169.43555}]}